Effects of 12 weeks of treatment with intravenously administered bococizumab, a humanized monoclonal antibody blocking proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects on high‐dose statin

Publisher: John Wiley & Sons Inc

E-ISSN: 1755-5922|36|1|1755-5922.12308-1755-5922.12308

ISSN: 1755-5914

Source: CARDIOVASCULAR THERAPEUTICS (ELECTRONIC), Vol.36, Iss.1, 2018-02, pp. : n/a-n/a

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content